Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen(DPANDA) Study

Beijing Institute of Heart, Lung and Blood Vessel Diseases

Status: Enrolling

Conditions: Aortic Aneurysm; Aortic Dissection

Study type: Observational

Funder types: Other

Identifiers

NCT03233087

DPANDA

Details and patient eligibility

About

The registry study aims to determine serial biomarkers to diagnosis and prognosis of aortic aneurysm/aortic dissection.

Full description

The study aims to investigate the role of candidate biomarkers in the diagnosis and prognosis of AA and AD. In the diagnosis part, we begin with a discovery phase where individually matched case-control study. Patients within each disease outcomes (i.e. AD, AMI, PE, AA without AD and healthy controls) are age and sex matched and retrospectively included.In the prognosis part of the study, patients with confirmed AA and AD are enrolled. The primary outcome is the all-cause mortality based on the death certificates. The secondary outcome is the in-hospital mortality according to the patients'medical records.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Retrospective

• All patients who were referred to the surgical service for evaluation and management of aortic dissection were included.

Perspective

• Patients with initial suspicion of having AAD were perspectively enrolled.

Exclusion criteria

Retrospective

• Patients who received packed red blood cells, whole blood, or platelets less than 10 days before the blood sample was taken;
• Patients with aortic trauma, pseudo aneurysm, history of heart failure, renal dysfunction, severe pulmonary diseases, or active cancer;
• Patients who entered the hospital for checkups after surgery.

Perspective

• Patients in whom there is little or no suspicion of a life-threatening disease;
• Patients with confirmed acute myocardial infarction,angina or pulmonary embolism
• The symptoms were clearly not related to AD (e.g. pleurisy, pneumonia, acute abdominal diseases).

Trial design

1,500 participants in 3 patient groups

Top third of subjects based levels of selected biomarker.

Middle third of subjects based levels of selected biomarker.

Bottom third ofsubjects based levels of selected biomarker.